
Simulations Plus (SLP) Stock Forecast & Price Target
Simulations Plus (SLP) Analyst Ratings
Bulls say
Simulations Plus Inc. has demonstrated strong organizational growth, with an impressive 30% increase in the total dollar value of awarded work not yet recognized in backlog in Q3 year-over-year. The company has also experienced notable improvements in proposal activity within the biotech sector, signaling increased confidence among clients as they navigate their budgeting cycles. Additionally, the software segment reported a substantial 22% year-over-year revenue increase, alongside a modest growth in services revenue, highlighting the company's robust position in the pharmaceutical research software market.
Bears say
Simulations Plus Inc reported a year-over-year revenue decline of 6% in F4Q:25, despite a full-year increase of 13%, indicating potential underlying weakness in its business model. The company's guidance for F1Q:26 anticipates further revenue decline of 3% to 5%, which raises concerns about its ability to maintain growth relative to competitors in the pharmaceutical technology sector. Additionally, the organic growth rate has been stagnant, with growth of only 5% in the first half of the fiscal year followed by declines of 3% and 6.5% in the latter quarters, signaling a troubling trend for the company's revenue trajectory.
This aggregate rating is based on analysts' research of Simulations Plus and is not a guaranteed prediction by Public.com or investment advice.
Simulations Plus (SLP) Analyst Forecast & Price Prediction
Start investing in Simulations Plus (SLP)
Order type
Buy in
Order amount
Est. shares
0 shares